ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Alzamend Neuro, Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026
$1.33+0.03 (+2.31%)
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -356.1% | -373.2% | |
| Return on assets | – | -213.5% | -262.6% | |
| Current ratio | – | 3.24 | – | |
| Interest coverage | – | -34.8× | -1324.5× | |
| Diluted shares | – | 0M | 3M |
Cash use needs five years of cash flow figures
Alzamend Neuro does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 5 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.77M
- Cash generatingOperating cash flow above zero-$8.07M
- Return on assets improvedROA up on the prior year-714.8% → -190.6%
- Earnings backed by cashOperating cash flow above net income-$8.07M vs -$8.77M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise0M → 3M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –